X
[{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avalo Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor Event","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma (NEA)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Apollo Therapeutics","pharmaFlowCategory":"D","amount":"$89.0 million","upfrontCash":"$15.0 million","newsHeadline":"Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"ES Therapeutics","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Avalo Sells Economic Rights to Previously Out-Licensed Assets for $5 Million","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"AUG Therapeutics","pharmaFlowCategory":"D","amount":"$45.1 million","upfrontCash":"$0.1 million","newsHeadline":"Avalo Enters into Agreement to Divest AVTX-800 Series","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Avalo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avalo Acquires Anti-IL-1\u03b2 mAb and Announces Private Placement Financing of up to $185 Million","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Commodore Capital","pharmaFlowCategory":"D","amount":"$185.0 million","upfrontCash":"$115.6 million","newsHeadline":"Avalo Acquires Anti-IL-1\u03b2 mAb and Announces Private Placement Financing of up to $185 Million","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by Avalo Therapeutics
Filters
Companies By Therapeutic Area
Details:
Through the acquisition of AlmataBio, Avalo acquires Phase 2-ready, AVTX-009, a humanized monoclonal antibody (IgG4) that binds to interleukin-1β, being developed for hidradenitis suppurativa.
Lead Product(s):
AVTX-009
Therapeutic Area: Dermatology
Product Name: AVTX-009
Highest Development Status: Phase I
Product Type: Large molecule
Recipient:
AlmataBio
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Acquisition
March 27, 2024
Details:
The net proceeds will be used for the developement of AVTX-009, a humanized monoclonal antibody (IgG4) that binds to interleukin-1β, being developed for hidradenitis suppurativa.
Lead Product(s):
AVTX-009
Therapeutic Area: Dermatology
Product Name: AVTX-009
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Commodore Capital
Deal Size: $185.0 million
Upfront Cash: $115.6 million
Deal Type: Private Placement
March 27, 2024
Details:
Under the divestiture, AUG gains rights, title and interest in, assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose). AVTX-801 is a therapeutic dose of D-galactose currently in development for the treatment of phosphoglucomutase 1 deficiency.
Lead Product(s):
Alpha-D-Galactose
Therapeutic Area: Genetic Disease
Product Name: AVTX-801
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
AUG Therapeutics
Deal Size: $45.1 million
Upfront Cash: $0.1 million
Deal Type: Divestment
September 12, 2023
Details:
AVTX-002 (quisovalimab) is a fully human monoclonal antibody (mAb), directed against human LIGHT, and investigated for the treatment of patients with poorly controlled non-eosinophilic asthma
Lead Product(s):
Quisovalimab
Therapeutic Area: Pulmonary/Respiratory Diseases
Product Name: AVTX-002
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 26, 2023
Details:
AVTX-002 is a fully human monoclonal antibody, directed against human LIGHT. AVTX-002 is currently in Phase 2 development for non-eosinophilic asthma (NEA) with proof-of-concept data in inflammatory bowel diseases (IBD) and COVID-19 acute respiratory distress syndrome (ARDS).
Lead Product(s):
AVTX-002
Therapeutic Area: Pulmonary/Respiratory Diseases
Product Name: AVTX-002
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
SVB Securities
Deal Size: $15.0 million
Upfront Cash: Undisclosed
Deal Type: Public Offering
February 02, 2023
Details:
AVTX-002 is a fully human monoclonal antibody (mAb), directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes).
Lead Product(s):
Monoclonal Antibody
Therapeutic Area: Pulmonary/Respiratory Diseases
Product Name: AVTX-002
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 17, 2023
Details:
AVTX-007 is a fully human monoclonal antibody for the treatment of Still’s Disease, including adult-onset Still’s disease (AOSD) and systemic juvenile jdiopathic Arthritis (SJIA).
Lead Product(s):
AVTX-007
Therapeutic Area: Pulmonary/Respiratory Diseases
Product Name: AVTX-007
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
ES Therapeutics
Deal Size: $5.0 million
Upfront Cash: Undisclosed
Deal Type: Agreement
November 07, 2022
Details:
The active pharmaceutical ingredient (API) in AVTX-803 is L-fucose an oral formulation of L-fucose that enhances fucosylation of proteins in the absence of a functioning GDP-fucose transporter, partially restoring protein function.
Lead Product(s):
L-Fucose
Therapeutic Area: Genetic Disease
Product Name: AVTX-803
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 02, 2022
Details:
Under the terms of the agreement, Apollo will assume responsibility for the future development of AVTX-007 (camoteskimab), including the ongoing clinical trial. Apollo will lead future clinical development in its selected therapeutic indications.
Lead Product(s):
AVTX-002
Therapeutic Area: Pulmonary/Respiratory Diseases
Product Name: AVTX-002
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Apollo Therapeutics
Deal Size: $89.0 million
Upfront Cash: $15.0 million
Deal Type: Licensing Agreement
August 01, 2022
Details:
MDGN-002 (AVTX-002) is a fully human anti-LIGHT, monoclonal antibody in development for the treatment of acute respiratory distress syndrome (ARDS), the treatment of inflammatory bowel disease (IBD) and the treatment of non-eosinophilic asthma.
Lead Product(s):
AVTX-002
Therapeutic Area: Pulmonary/Respiratory Diseases
Product Name: MDGN-002
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 18, 2022